Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lineage Commitment01:21

Lineage Commitment

4.6K
Commitment is the  process whereby stem cells:
4.6K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

4.4K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.4K
Methods of Nuclear Reprogramming01:24

Methods of Nuclear Reprogramming

2.3K
Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for...
2.3K
Chromatin Modification in iPS Cells01:32

Chromatin Modification in iPS Cells

2.3K
Chromatin modification alters gene expression; therefore, scientists can add histone-modifying enzymes, histone variants, and chromatin remodeling complexes to somatic cells to aid reprogramming into pluripotent stem (iPS) cells.
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
2.3K
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

2.9K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.9K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

4.2K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment-related pathways.

British journal of haematology·2026
Same author

Menin-dependent megakaryocyte proliferation and fibrosis in myeloproliferative neoplasms.

Cancer cell·2026
Same author

Linezolid Acts as a Selective Inhibitor of the JAK2 <sup>V617F</sup> Mutation.

bioRxiv : the preprint server for biology·2026
Same author

Long term outcomes of idasanutlin therapy in hydroxyurea-refractory polycythemia vera patients.

Leukemia & lymphoma·2026
Same author

Inhibition of the EBF1-ITGB8 Axis in Bone Marrow Niche Ameliorates Hallmarks of Myelofibrosis.

bioRxiv : the preprint server for biology·2026
Same author

Artificial intelligence differentiates prefibrotic primary myelofibrosis with thrombocytosis from essential thrombocythemia using digitized bone marrow biopsy images.

Leukemia·2026

Related Experiment Video

Updated: Apr 11, 2026

Hemogenic Reprogramming of Human Fibroblasts by Enforced Expression of Transcription Factors
11:42

Hemogenic Reprogramming of Human Fibroblasts by Enforced Expression of Transcription Factors

Published on: November 4, 2019

6.6K

Role of epigenetic reprogramming in hematopoietic stem cell function.

Camelia Iancu-Rubin1, Ronald Hoffman

  • 1The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Current Opinion in Hematology
|June 8, 2015
PubMed
Summary

Small molecules called chromatin-modifying agents (CMAs) can reverse gene silencing in hematopoietic stem cells (HSCs) during ex vivo expansion. This reprogramming strategy shows promise for manufacturing increased numbers of transplantable HSCs without malignant transformation.

More Related Videos

Reprogramming Mouse Embryonic Fibroblasts with Transcription Factors to Induce a Hemogenic Program
11:00

Reprogramming Mouse Embryonic Fibroblasts with Transcription Factors to Induce a Hemogenic Program

Published on: December 16, 2016

7.8K
Direct Lineage Reprogramming of Adult Mouse Fibroblast to Erythroid Progenitors
11:46

Direct Lineage Reprogramming of Adult Mouse Fibroblast to Erythroid Progenitors

Published on: December 14, 2018

7.0K

Related Experiment Videos

Last Updated: Apr 11, 2026

Hemogenic Reprogramming of Human Fibroblasts by Enforced Expression of Transcription Factors
11:42

Hemogenic Reprogramming of Human Fibroblasts by Enforced Expression of Transcription Factors

Published on: November 4, 2019

6.6K
Reprogramming Mouse Embryonic Fibroblasts with Transcription Factors to Induce a Hemogenic Program
11:00

Reprogramming Mouse Embryonic Fibroblasts with Transcription Factors to Induce a Hemogenic Program

Published on: December 16, 2016

7.8K
Direct Lineage Reprogramming of Adult Mouse Fibroblast to Erythroid Progenitors
11:46

Direct Lineage Reprogramming of Adult Mouse Fibroblast to Erythroid Progenitors

Published on: December 14, 2018

7.0K

Area of Science:

  • Stem cell biology
  • Epigenetics
  • Hematopoiesis

Background:

  • Hematopoietic stem cells (HSCs) possess epigenetic regulatory networks crucial for their fate.
  • Ex vivo expansion of human HSCs has been limited by epigenetic silencing of HSC gene-expression patterns, leading to cell depletion or stagnation.
  • Reprogramming cultured CD34+ cells is a key area of research for expanding HSC numbers.

Purpose of the Study:

  • To review recent advancements in using small molecules to reprogram CD34+ cells for ex vivo expansion.
  • To explore strategies for overcoming epigenetic silencing that hinders HSC expansion.

Main Methods:

  • Utilizing chromatin-modifying agents (CMAs) to reactivate silenced HSC gene-expression patterns.
  • Investigating the effects of CMAs on HSC self-renewal and progenitor cell reprogramming.
  • Assessing the safety of CMA treatment regarding malignant transformation.

Main Results:

  • CMAs effectively reactivate silenced gene-expression patterns in ex vivo cultured HSCs.
  • CMAs promote symmetrical self-renewal divisions and reprogram progenitor cells, leading to increased HSC numbers.
  • Ex vivo treatment with CMAs has not resulted in malignant transformation of the cell product.

Conclusions:

  • Transient exposure to CMAs can reverse HSC gene silencing during ex vivo culture.
  • This reprogramming approach offers a potential strategy for clinically relevant manufacturing of expanded HSCs.
  • Successful implementation could lead to improved HSC transplantation therapies.